CNTB

NASDAQ open

Connect Biopharma Holdings

0.59 USD
▼-0.04-6.08%
盘后 0.74 0.00%
2026-11-20
市值
$38.05M
市盈率
—
EPS
-1.14
股息率
—
52 周区间
0.55 – 3.82
成交量
309.25K
Beta
-0.18
目标价
5.71
52W 低 0.5552W 高 3.82
价格走势

公司简介

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Rα in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.